{"id":72455,"date":"2026-08-13T17:55:05","date_gmt":"2026-08-13T09:55:05","guid":{"rendered":"https:\/\/flcube.com\/?p=72455"},"modified":"2026-08-13T17:55:06","modified_gmt":"2026-08-13T09:55:06","slug":"insilico-medicine-and-thpharma-launch-ai-research-collaboration-to-build-reverse-translation-drug-discovery-strategy-around-phase-3-candidate-thp-001","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72455","title":{"rendered":"Insilico Medicine and THPharma Launch AI Research Collaboration to Build &#8216;Reverse Translation&#8217; Drug Discovery Strategy Around Phase 3 Candidate THP-001"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3696:HKG\">HKG: 3696<\/a>) announced a <strong>research collaboration<\/strong> with <strong>THPharma<\/strong>, a Korean company focused on <strong>metabolic disease drug development<\/strong>, aiming to leverage <strong>biology-based AI<\/strong> to establish a <strong>&#8220;reverse translation&#8221; strategy<\/strong> for drug discovery \u2014 an approach that begins with clear pharmacodynamic data from preclinical-stage candidates and works backwards to identify potential <strong>indications, mechanisms of action, and biomarker systems<\/strong>, thereby expanding the application boundaries of existing drug pipelines.<\/p>\n\n\n\n<h2 id=\"h-collaboration-milestone\" class=\"wp-block-heading\">Collaboration Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Insilico Medicine (HKG: 3696) \u00d7 THPharma (South Korea)<\/td><\/tr><tr><td><strong>Collaboration Type<\/strong><\/td><td>Research collaboration \u2014 biology-based AI<\/td><\/tr><tr><td><strong>Strategy<\/strong><\/td><td>&#8220;Reverse translation&#8221; drug discovery: pharmacodynamic data \u2192 indications, mechanisms, biomarkers<\/td><\/tr><tr><td><strong>Focus Areas<\/strong><\/td><td>Heart failure, fatty liver, obesity, and broader metabolic diseases<\/td><\/tr><tr><td><strong>Pilot Asset<\/strong><\/td><td>THP-001 (gene expression analysis and meta-analysis)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>13 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pilot-program-thp-001\" class=\"wp-block-heading\">Pilot Program \u2013 THP-001<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asset Status:<\/strong> THPharma&#8217;s core candidate, currently in <strong>global Phase 3 clinical trials<\/strong> for the treatment of <strong>type 2 diabetes<\/strong> and <strong>essential hypertension<\/strong><\/li>\n\n\n\n<li><strong>AI Workstreams:<\/strong> <strong>Gene expression analysis<\/strong> and <strong>meta-analysis<\/strong> to reverse-translate pharmacodynamic signals into new indications and mechanisms<\/li>\n\n\n\n<li><strong>Strategic Purpose:<\/strong> Demonstrate the reverse-translation workflow on a late-stage asset with rich clinical data, maximizing the chance of identifying new application boundaries for an existing pipeline asset<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-expansion-roadmap\" class=\"wp-block-heading\">Expansion Roadmap<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Following the pilot project with <strong>THP-001<\/strong> and the establishment of relevant analytical workflows, both parties plan to <strong>extend this methodology to more metabolic disease programs<\/strong> in THPharma&#8217;s pipeline \u2014 particularly candidate projects utilizing <strong>innovative drug delivery systems (DDS)<\/strong> that have already generated preclinical <strong>efficacy, safety, and toxicology data<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Repurposing Economics:<\/strong> Reverse translation targets one of pharma&#8217;s most underexploited value pools \u2014 extracting new indications from assets already rich in pharmacodynamic and clinical data, at a fraction of de novo discovery cost.<\/li>\n\n\n\n<li><strong>Complementary Strengths:<\/strong> The pairing brings together Insilico Medicine&#8217;s AI-driven biology engine with THPharma&#8217;s metabolic disease pipeline and DDS technology, a structure well suited to asset-light, data-driven pipeline expansion.<\/li>\n\n\n\n<li><strong>Metabolic Disease Momentum:<\/strong> Heart failure, fatty liver disease, and obesity remain among the most commercially active therapeutic frontiers, amplified by the current weight-loss drug boom.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Financial terms, timelines for analytical workflow establishment, and downstream licensing arrangements were not disclosed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the collaboration&#8217;s research outcomes and potential pipeline expansion. Actual results may differ due to risks including analytical validation, clinical progress of THP-001, and competitive dynamics in metabolic disease.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced a research collaboration with THPharma, a Korean company focused on&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[99,4514,164,4895],"class_list":["post-72455","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-hkg-3696","tag-insilico-medicine","tag-thpharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine and THPharma Launch AI Research Collaboration to Build &#039;Reverse Translation&#039; Drug Discovery Strategy Around Phase 3 Candidate THP-001 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced a research collaboration with THPharma, a Korean company focused on metabolic disease drug development, aiming to leverage biology-based AI to establish a &quot;reverse translation&quot; strategy for drug discovery \u2014 an approach that begins with clear pharmacodynamic data from preclinical-stage candidates and works backwards to identify potential indications, mechanisms of action, and biomarker systems, thereby expanding the application boundaries of existing drug pipelines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72455\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine and THPharma Launch AI Research Collaboration to Build &#039;Reverse Translation&#039; Drug Discovery Strategy Around Phase 3 Candidate THP-001\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced a research collaboration with THPharma, a Korean company focused on metabolic disease drug development, aiming to leverage biology-based AI to establish a &quot;reverse translation&quot; strategy for drug discovery \u2014 an approach that begins with clear pharmacodynamic data from preclinical-stage candidates and works backwards to identify potential indications, mechanisms of action, and biomarker systems, thereby expanding the application boundaries of existing drug pipelines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72455\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T09:55:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-13T09:55:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72455#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72455\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine and THPharma Launch AI Research Collaboration to Build &#8216;Reverse Translation&#8217; Drug Discovery Strategy Around Phase 3 Candidate THP-001\",\"datePublished\":\"2026-08-13T09:55:05+00:00\",\"dateModified\":\"2026-08-13T09:55:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72455\"},\"wordCount\":401,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"HKG: 3696\",\"Insilico Medicine\",\"THPharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72455#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72455\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72455\",\"name\":\"Insilico Medicine and THPharma Launch AI Research Collaboration to Build 'Reverse Translation' Drug Discovery Strategy Around Phase 3 Candidate THP-001 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-13T09:55:05+00:00\",\"dateModified\":\"2026-08-13T09:55:06+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced a research collaboration with THPharma, a Korean company focused on metabolic disease drug development, aiming to leverage biology-based AI to establish a \\\"reverse translation\\\" strategy for drug discovery \u2014 an approach that begins with clear pharmacodynamic data from preclinical-stage candidates and works backwards to identify potential indications, mechanisms of action, and biomarker systems, thereby expanding the application boundaries of existing drug pipelines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72455#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72455\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72455#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine and THPharma Launch AI Research Collaboration to Build &#8216;Reverse Translation&#8217; Drug Discovery Strategy Around Phase 3 Candidate THP-001\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine and THPharma Launch AI Research Collaboration to Build 'Reverse Translation' Drug Discovery Strategy Around Phase 3 Candidate THP-001 - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced a research collaboration with THPharma, a Korean company focused on metabolic disease drug development, aiming to leverage biology-based AI to establish a \"reverse translation\" strategy for drug discovery \u2014 an approach that begins with clear pharmacodynamic data from preclinical-stage candidates and works backwards to identify potential indications, mechanisms of action, and biomarker systems, thereby expanding the application boundaries of existing drug pipelines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72455","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine and THPharma Launch AI Research Collaboration to Build 'Reverse Translation' Drug Discovery Strategy Around Phase 3 Candidate THP-001","og_description":"Insilico Medicine (HKG: 3696) announced a research collaboration with THPharma, a Korean company focused on metabolic disease drug development, aiming to leverage biology-based AI to establish a \"reverse translation\" strategy for drug discovery \u2014 an approach that begins with clear pharmacodynamic data from preclinical-stage candidates and works backwards to identify potential indications, mechanisms of action, and biomarker systems, thereby expanding the application boundaries of existing drug pipelines.","og_url":"https:\/\/flcube.com\/?p=72455","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-13T09:55:05+00:00","article_modified_time":"2026-08-13T09:55:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72455#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72455"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine and THPharma Launch AI Research Collaboration to Build &#8216;Reverse Translation&#8217; Drug Discovery Strategy Around Phase 3 Candidate THP-001","datePublished":"2026-08-13T09:55:05+00:00","dateModified":"2026-08-13T09:55:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72455"},"wordCount":401,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","HKG: 3696","Insilico Medicine","THPharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72455#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72455","url":"https:\/\/flcube.com\/?p=72455","name":"Insilico Medicine and THPharma Launch AI Research Collaboration to Build 'Reverse Translation' Drug Discovery Strategy Around Phase 3 Candidate THP-001 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-13T09:55:05+00:00","dateModified":"2026-08-13T09:55:06+00:00","description":"Insilico Medicine (HKG: 3696) announced a research collaboration with THPharma, a Korean company focused on metabolic disease drug development, aiming to leverage biology-based AI to establish a \"reverse translation\" strategy for drug discovery \u2014 an approach that begins with clear pharmacodynamic data from preclinical-stage candidates and works backwards to identify potential indications, mechanisms of action, and biomarker systems, thereby expanding the application boundaries of existing drug pipelines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72455#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72455"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72455#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine and THPharma Launch AI Research Collaboration to Build &#8216;Reverse Translation&#8217; Drug Discovery Strategy Around Phase 3 Candidate THP-001"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72455"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72455\/revisions"}],"predecessor-version":[{"id":72457,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72455\/revisions\/72457"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}